The IMbrave 150 trial demonstrated that, compared to sorafenib, the combination of atezolizumab (PD-L1 inhibitor) and bevacizumab (VEGF inhibitor) had improved overall (OS) and progression free survival (PFS) in patients with unresectable HCC (9). This evidence concerns the gene CD274 and hepatocellular carcinoma.